Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy
- 209 Downloads
To develop an integrated metric of non-COX-1-dependent platelet function (NCDPF) to measure the temporal response to aspirin in healthy volunteers and diabetics. NCDPF on aspirin demonstrates wide variability, despite suppression of COX-1. Although a variety of NCDPF assays are available, no standard exists and their reproducibility is not established. We administered 325 mg/day aspirin to two cohorts of volunteers (HV1, n = 52, and HV2, n = 96) and diabetics (DM, n = 74) and measured NCDPF using epinephrine, collagen, and ADP aggregometry and PFA100 (collagen/epi) before (Pre), after one dose (Post), and after several weeks (Final). COX-1 activity was assessed with arachidonic acid aggregometry (AAA). The primary outcome of the study, the platelet function score (PFS), was derived from a principal components analysis of NCDPF measures. The PFS strongly correlated with each measure of NCDPF in each cohort. After 2 or 4 weeks of daily aspirin the Final PFS strongly correlated (r > 0.7, P < 0.0001) and was higher (P < 0.01) than the Post PFS. The magnitude and direction of the change in PFS (Final–Post) in an individual subject was moderately inversely proportional to the Post PFS in HV1 (r = −0.45), HV2 (r = −0.54), DM (r = −0.68), P < 0.0001 for all. AAA remained suppressed during aspirin therapy. The PFS summarizes multiple measures of NCDPF. Despite suppression of COX-1 activity, NCDPF during aspirin therapy is predictably dynamic: those with heightened NCDPF continue to decline whereas those with low/normal NCDPF return to pre-aspirin levels over time.
KeywordsAspirin Platelets Light transmittance aggregometry PFA100 Principal components analysis
This study was funded by institutional funds provided by the Duke Institute for Genome Sciences & Policy, a National Institutes of Health (NIH) T32 Training grant (5T32HL007101 to DV), a grant (5UL1RR024128) from the National Center for Research Resources (NCRR), a component of the NIH, and NIH Roadmap for Medical Research, a grant (5RC1GM091083 to GSG) from the National Institutes of General Medical Sciences, and a grant (5U01DD000014-06 to TLO) from the Centers for Disease Control and Prevention. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.
- 1.Soni A (2007) Aspirin use among the adult U.S. noninstitutionalized population, with and without indicators of heart disease, 2005. http://meps.ahrq.gov/mepsweb/data_files/publications/st179/stat179.pdf. Accessed 11 January 2012
- 7.Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, Fallin MD, Wilson AF, Bray PF, Becker LC, Becker DM (2007) Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 115(19):2490–2496PubMedCrossRefGoogle Scholar
- 8.Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US (2007) Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115(25):3156–3164PubMedCrossRefGoogle Scholar
- 9.Frelinger AL III, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD (2009) Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 120(25):2586–2596. doi: 10.1161/circulationaha.109.900589 PubMedCrossRefGoogle Scholar
- 14.Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, Davi G, Patrono C (2009) Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “Resistance”. J Am Coll Cardiol 53(8):667–677PubMedCrossRefGoogle Scholar
- 19.Frelinger AL III, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD (2006) Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 113(25):2888–2896PubMedCrossRefGoogle Scholar
- 24.Williams MS, Weiss EJ, Sabatine MS, Simon DI, Bahou WF, Becker LC, Parise LV, Dauerman HL, French PA, Smyth SS, Becker RC (2010) Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development. Arterioscl Thromb Vasc Biol 30(12):2372–2384. doi: 10.1161/ATVBAHA.110.218131 PubMedCrossRefGoogle Scholar
- 25.Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, Ozaki Y, Sakata Y (2006) Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 4(6):1271–1278. doi: 10.1111/j.1538-7836.2006.01958.x PubMedCrossRefGoogle Scholar
- 27.Mathias R, Kim Y, Sung H, Yanek L, Mantese V, Hererra-Galeano E, Ruczinski I, Wilson A, Faraday N, Becker L, Becker D (2010) A combined genome-wide linkage and association approach to find susceptibility loci for platelet function phenotypes in European American and African American families with coronary artery disease. BMC Med Genomics 3(1):22PubMedCrossRefGoogle Scholar
- 28.Johnson AD, Yanek LR, Chen M-H, Faraday N, Larson MG, Tofler G, Lin SJ, Kraja AT, Province MA, Yang Q, Becker DM, O’Donnell CJ, Becker LC (2010) Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet 42(7):608–613. http://www.nature.com/ng/journal/v42/n7/suppinfo/ng.604_S1.html Google Scholar
- 32.Hayward CPM, Harrison P, Cattaneo M, Ortel TL, Rao AK, The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2006) Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 4(2):312–319PubMedCrossRefGoogle Scholar